The latest monovalent coronavirus disease (COVID-19) vaccine has a vaccine efficacy (VE) of 54 percent against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. announced that it would be provided. the study Published in the February 1 issue of the Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Ruth Link-Gelles, Ph.D., of the CDC in Atlanta, and colleagues analyzed data from the Pharmacy Testing Program: Increasing Community Access to Testing for SARS-CoV-2 and found that the latest 2023-2024 estimates for symptomatic SARS-CoV Estimated new coronavirus infection (VE). -2 Infection with monovalent XBB.1.5-derived vaccine.
Researchers found that among 9,222 eligible tests, the overall VE for adults 18 years and older was 54% at a median of 52 days post-vaccination. In a total of 2,199 tests performed at laboratories that perform SGTF testing, VE 60 to 119 days after vaccination was 49% for tests showing spike gene target failure (SGTF) and 49% for tests without SGTF. It was 60%.
“Vaccination provided protection against infections caused by JN.1 and infections caused by XBB-related strains, especially for less severe diseases, especially if time has elapsed since vaccination. “We expect the effectiveness to diminish over time,” the authors write. “Everyone six months of age and older should always have up-to-date COVID-19 vaccinations, including up-to-date vaccinations.”
For more information:
Ruth Link-Gelles et al, Early estimates of the 2023-2024 update (monovalent XBB.1.5), symptomatic SARS-CoV-2 infections caused by cocirculating omicron variants among immunocompetent adults Efficacy of COVID-19 Vaccines against Diseases—Increasing Community Access to Testing Programs, United States, September 2023 to January 2024; MMWR.Morbidity and Mortality Weekly Report (2024). DOI: 10.15585/mmwr.mm7304a2
